Back to Search Start Over

Circulating serotypes and genotypes of dengue virus during the 2023 outbreak in Eastern Nepal.

Authors :
Bharati N
Dumre SP
Shah Y
Nabesima T
Dhimal M
Pandey S
Kapandji M
Takamatsu Y
Urano T
Pandey BD
Morita K
Ngwe Tun MM
Pandey K
Source :
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2024 Oct; Vol. 174, pp. 105721. Date of Electronic Publication: 2024 Aug 30.
Publication Year :
2024

Abstract

Dengue virus (DENV) is one of the most significant mosquito-borne diseases in Nepal. In 2023, DENV outbreaks began in Eastern Nepal, near the border with India, and rapidly spread nationwide. The study aims to describe the outbreak's epidemiological pattern, laboratory characteristics, DENV serotypes, and genotypes. A hospital-based cross-sectional study was conducted in four hospitals in Jhapa, Eastern Nepal, in 2023. Acute serum samples were obtained from dengue suspected patients within 7 days of illness and subjected to virus isolation, conventional and real-time polymerase chain reaction (RT-PCR), and phylogenetic analysis. Out of 60 samples, 42 (70 %), 11 (18.3 %) and 7 (11.7 %) were primary, secondary and non-dengue infection, respectively. Among 53 dengue confirmed patients, 46 (86.7 %) were positive for NS1 and 12 (22.6 %) were positive for both NS1 and IgM. Out of 42 dengue isolates, a new clade of the cosmopolitan genotype of DENV-2 was the most prevalent (28, 66.7 %), followed by genotype III of DENV-3 (11, 26.2 %) and genotype V of DENV-1 (3, 7.1 %). Genotype III of DENV-3 was first introduced in 2022-2023 in Nepal. Phylogenetic analysis of the E gene revealed the DENV-2 isolates from Nepal had 98 % homologous nucleotide similarity with the strains from India and Bangladesh. To our knowledge, this is the first report of circulating serotypes and genotypes of DENV in Jhapa. Integrating molecular findings into the dengue control plan can enhance surveillance efforts, monitor disease trends, and implement proactive measures to reduce the burden of dengue and prevent fatalities in future outbreaks.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-5967
Volume :
174
Database :
MEDLINE
Journal :
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Publication Type :
Academic Journal
Accession number :
39232301
Full Text :
https://doi.org/10.1016/j.jcv.2024.105721